News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
714,691 Results
Type
Article (42328)
Company Profile (436)
Press Release (671927)
Multimedia
Podcasts (78)
Webinars (13)
Section
Business (208749)
Career Advice (2021)
Deals (36008)
Drug Delivery (104)
Drug Development (83583)
Employer Resources (173)
FDA (16433)
Job Trends (15098)
News (352813)
Policy (33084)
Tag
Academia (2643)
Accelerated approval (6)
Adcomms (24)
Allergies (87)
Alliances (50962)
ALS (94)
Alzheimer's disease (1431)
Antibody-drug conjugate (ADC) (139)
Approvals (16424)
Artificial intelligence (268)
Autoimmune disease (25)
Automation (16)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (330)
Bladder cancer (82)
Brain cancer (27)
Breast cancer (287)
Cancer (2319)
Cardiovascular disease (186)
Career advice (1689)
Career pathing (30)
CAR-T (157)
Cell therapy (444)
Cervical cancer (19)
Clinical research (67784)
Collaboration (877)
Compensation (537)
Complete response letters (24)
COVID-19 (2648)
CRISPR (45)
C-suite (253)
Cystic fibrosis (105)
Data (2238)
Decentralized trials (2)
Denatured (28)
Depression (51)
Diabetes (275)
Diagnostics (6428)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (107)
Drug shortages (26)
Duchenne muscular dystrophy (100)
Earnings (87868)
Editorial (40)
Employer branding (21)
Employer resources (147)
Events (115967)
Executive appointments (743)
FDA (17712)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (783)
Gene editing (113)
Generative AI (20)
Gene therapy (328)
GLP-1 (747)
Government (4503)
Grass and pollen (4)
Guidances (65)
Healthcare (19146)
Huntington's disease (24)
IgA nephropathy (30)
Immunology and inflammation (130)
Indications (30)
Infectious disease (2793)
Inflammatory bowel disease (143)
Inflation Reduction Act (11)
Influenza (52)
Intellectual property (98)
Interviews (311)
IPO (16789)
IRA (43)
Job creations (3701)
Job search strategy (1434)
Kidney cancer (10)
Labor market (38)
Layoffs (496)
Leadership (18)
Legal (7986)
Liver cancer (76)
Lung cancer (328)
Lymphoma (156)
Machine learning (7)
Management (58)
Manufacturing (313)
MASH (70)
Medical device (13526)
Medtech (13531)
Mergers & acquisitions (19758)
Metabolic disorders (719)
Multiple sclerosis (82)
NASH (19)
Neurodegenerative disease (102)
Neuropsychiatric disorders (33)
Neuroscience (2004)
NextGen: Class of 2025 (6755)
Non-profit (4550)
Now hiring (39)
Obesity (385)
Opinion (223)
Ovarian cancer (77)
Pain (91)
Pancreatic cancer (84)
Parkinson's disease (155)
Partnered (21)
Patents (236)
Patient recruitment (111)
Peanut (47)
People (58688)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21299)
Phase II (29911)
Phase III (22115)
Pipeline (1222)
Policy (146)
Postmarket research (2601)
Preclinical (9138)
Press Release (67)
Prostate cancer (110)
Psychedelics (37)
Radiopharmaceuticals (263)
Rare diseases (404)
Real estate (6015)
Recruiting (66)
Regulatory (22747)
Reports (46)
Research institute (2416)
Resumes & cover letters (351)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (77)
Series A (139)
Series B (90)
Service/supplier (11)
Sickle cell disease (57)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3762)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (39)
The Weekly (48)
Vaccines (706)
Venture capitalists (43)
Weight loss (255)
Women's health (37)
Worklife (17)
Date
Today (186)
Last 7 days (893)
Last 30 days (2701)
Last 365 days (33895)
2025 (10970)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32186)
2013 (27111)
2012 (29221)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (58)
Alaska (7)
Arizona (239)
Arkansas (14)
Asia (39259)
Australia (6532)
California (6258)
Canada (2025)
China (535)
Colorado (272)
Connecticut (288)
Delaware (150)
Europe (85810)
Florida (914)
Georgia (207)
Idaho (57)
Illinois (553)
India (25)
Indiana (311)
Iowa (12)
Japan (163)
Kansas (107)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (913)
Massachusetts (4753)
Michigan (222)
Minnesota (397)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (63)
New Hampshire (67)
New Jersey (1762)
New Mexico (30)
New York (1767)
North Carolina (1034)
North Dakota (8)
Northern California (2711)
Ohio (207)
Oklahoma (14)
Oregon (38)
Pennsylvania (1392)
Puerto Rico (12)
Rhode Island (34)
South America (1110)
South Carolina (23)
South Dakota (1)
Southern California (2336)
Tennessee (101)
Texas (925)
United States (23699)
Utah (183)
Virginia (149)
Washington D.C. (63)
Washington State (574)
West Virginia (3)
Wisconsin (55)
714,691 Results for "pliant therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Pliant Pops Poison Pill as Concentra Threat Looms
Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect shareholders against Tang Capital’s growing stake in the company.
March 14, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Pliant Stock Crashes After Suspension of Idiopathic Pulmonary Fibrosis Study
It is unclear why an independent data safety monitoring board recommended the suspension of Pliant’s Phase IIb/III BEACON-IPF study in idiopathic pulmonary fibrosis.
February 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
April 7, 2025
·
2 min read
Press Releases
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
March 13, 2025
·
3 min read
Press Releases
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results
March 4, 2025
·
8 min read
Business
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
Pliant Therapeutics, Inc., a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, announced the appointment of Steve Krognes to its Board of Directors.
June 13, 2024
·
5 min read
Press Releases
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
March 17, 2025
·
6 min read
Press Releases
Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
January 22, 2025
·
6 min read
Biotech Bay
Pliant Therapeutics to Participate in Upcoming Investor Events - May 1 2024
Pliant Therapeutics, Inc. today announced participation in the following May investor events.
May 1, 2024
·
2 min read
Press Releases
Pliant Therapeutics to Participate in Upcoming Investor Events
November 21, 2024
·
2 min read
1 of 71,470
Next
